<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052468</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258429</org_study_id>
    <secondary_id>AGO-OVAR9</secondary_id>
    <secondary_id>NORDIC-AGO-OVAR-9</secondary_id>
    <secondary_id>GERCOR-AGO-OVAR-9</secondary_id>
    <secondary_id>EU-20241</secondary_id>
    <nct_id>NCT00052468</nct_id>
  </id_info>
  <brief_title>Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer</brief_title>
  <acronym>AGO-OVAR9</acronym>
  <official_title>A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Society for Gynaecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AGO Study Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than
      carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer.

      PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with
      gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating
      patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare overall survival in patients with stage I-IV ovarian epithelial or fallopian
           tube cancer treated with adjuvant carboplatin and paclitaxel with or without
           gemcitabine.

        -  Compare response rates, progression-free survival, and duration of response in patients
           treated with these regimens.

        -  Compare toxic effects of these regimens in these patients.

        -  Compare quality of life of patients treated with these regimens.

      OUTLINE: This is a randomized, open-label, controlled, multicenter study. Patients are
      stratified according to FIGO stage (I-IIA vs IIB-IIIC and tumor no greater than 10 mm vs
      IIB-IIIC and tumor greater than 10 mm or IV), plan for interval surgical debulking (yes vs
      no), and participating center. Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive carboplatin IV over 30-60 minutes and paclitaxel IV over 3 hours
           on day 1 and gemcitabine IV over 30-60 minutes on days 1 and 8.

        -  Arm II: Patients receive carboplatin and paclitaxel as in arm I. Treatment in both arms
           repeats every 21 days for 6 to 10 courses in the absence of disease progression or
           unacceptable toxicity.

      Some patients undergo interval debulking surgery.

      Quality of life is assessed at baseline, after courses 3 and 6, and then at 3, 6, and 12
      months after completion of study.

      Patients are followed every 3 months for 2 years, every 6 months for up to 5 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 1,716 patients (858 per treatment arm) will be accrued for this
      study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Whole Study Period</time_frame>
    <description>Survival time is calculated from the date of enrollment into the study until the date of death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Whole Study Period</time_frame>
    <description>The progression-free survival is calculated for all patients from the date of enrollment until the date of first progressive disease or death, whichever occurs first</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Whole Study Period</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1742</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>TCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, Gemcitabine 800 mg/m2 day 1 + 8, q 21 days / 6 - 10 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel 175 mg/m2 day 1, Carboplatin AUC 5 day 1, q 21 days / 6 - 10 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TCG</intervention_name>
    <arm_group_label>TCG</arm_group_label>
    <other_name>Paclitaxel/Carboplatin/Gemcitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TC</intervention_name>
    <arm_group_label>TC</arm_group_label>
    <other_name>Paclitaxel/Carboplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed diagnosis of one of the following:

               -  Ovarian epithelial cancer

                    -  FIGO stage IA/B G3, IC-IV

               -  Fallopian tube cancer

               -  Extra-ovarian papillary serous tumor

          -  The following are ineligible:

               -  Low malignant-potential ovarian tumors (borderline tumors)

               -  Non-epithelial ovarian tumors

               -  Mixed Mullerian tumors

          -  Must have had definitive surgery within the past 6 weeks

          -  No symptomatic brain metastases

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 6 months

        Hematopoietic

          -  WBC at least 3,000/mm^3 OR

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

          -  Hemoglobin greater than 10 mg/dL

        Hepatic

          -  Bilirubin no greater than 2 times upper limit of normal

        Renal

          -  Glomerular filtration rate at least 50 mL/min

        Cardiovascular

          -  No congestive heart failure

          -  No myocardial infarction within the past 6 months

          -  No New York Heart Association class III or IV heart disease

          -  No prior atrial or ventricular arrhythmias

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No prior seizures or central nervous system disorder

          -  No prior severe hypersensitivity reaction to products containing Cremophor EL (e.g.,
             cyclosporine or vitamin K)

          -  No known hypersensitivity to compounds chemically related to carboplatin, gemcitabine,
             or paclitaxel

          -  No preexisting motor or sensory neuropathy greater than grade 1

          -  No other malignancy within the past 5 years except:

               -  Malignancies cured by surgery alone

               -  Carcinoma in situ of the cervix

               -  Adequately treated basal cell skin cancer

          -  No complete bowel obstruction

          -  No other concurrent severe medical condition that would preclude study participation

          -  No dementia or significantly altered mental status that would preclude study
             participation

          -  No concurrent severe active infection

          -  Geographically accessible for treatment and follow-up

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent immunotherapy

        Chemotherapy

          -  No prior chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent hormonal therapy except:

               -  Hormone replacement therapy

               -  Antiemetic steroids

        Radiotherapy

          -  No prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior surgery

        Other

          -  No other concurrent antineoplastic agents

          -  No other concurrent investigational drugs

          -  No other concurrent clinical trial enrollment
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas du Bois, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Dr. Horst-Schmidt-Kliniken</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Herrstedt</last_name>
    <role>Study Chair</role>
    <affiliation>Copenhagen County Herlev University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. Pujade-Lauraine, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hotel Dieu de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herlev Hospital - University Hospital of Copenhagen</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu de Paris</name>
      <address>
        <city>Paris</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentralkrankenhaus</name>
      <address>
        <city>Bremen</city>
        <zip>D-28205</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus</name>
      <address>
        <city>Dusseldorf</city>
        <zip>DOH-40217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>D-45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staedtische Kliniken Frankfurt am Main - Hoechst</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenklinik der MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vincentius Krankenhaus</name>
      <address>
        <city>Karlsruhe</city>
        <zip>D-76137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Schleswig-Holstein - Kiel Campus</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39108</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe - Universitaetsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>D-48129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaet Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>D-65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>N-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>du Bois A, Herrstedt J, Hardy-Bessard AC, MÃ¼ller HH, Harter P, Kristensen G, Joly F, Huober J, Avall-Lundqvist E, Weber B, Kurzeder C, Jelic S, Pujade-Lauraine E, Burges A, Pfisterer J, Gropp M, Staehle A, Wimberger P, Jackisch C, Sehouli J. Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer. J Clin Oncol. 2010 Sep 20;28(27):4162-9. doi: 10.1200/JCO.2009.27.4696. Epub 2010 Aug 23.</citation>
    <PMID>20733132</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I ovarian epithelial cancer</keyword>
  <keyword>stage II ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

